The European Circular Economy Project TREASoURcE to Install Stationary Battery Systems for Energy Storage Purposes at Two Demo Sites in Norway and Finland
22.3.2023 11:44:00 EET | Business Wire | Press release
As part of the four-year circular economy project TREASoURcE, a stationary Battery Energy Storage System (BESS) built with used electric vehicle batteries will be commissioned at two demo sites in Norway and Finland over the summer 2023. The demonstrations aim to increase knowledge of the batteries’ second life and their functionality and how stationary batteries can be used to balance electricity demand. The intended result is to accelerate the market uptake of this technology.
The selected demo sites are Rudskogen Motorsports Centre in Viken, Norway, and the municipally owned Lempäälä House in Lempäälä, Finland. The pilot is led by the Norwegian research organisation SINTEF and the battery systems will be supplied by the Norwegian company ECO STOR AS.
The system stores excess energy from solar panels which in turn is used to cut power peaks for the facilities. The BESS can thus be used to shift energy consumption to reduce the energy cost and provide stabilization for the entire power grid. The use of second-life batteries helps to reduce environmental impacts and save critical minerals and other natural resources by extending the product life cycle.
Rudskogen is a large motorsport centre that was selected by the Norwegian government as the national motorsport arena in 2005. Rudskogen will have a BESS with a rated capacity of 120 kWh and rated power of 60 kW.
“Rudskogen Motorsports Center wishes to choose good and sustainable solutions in connection with the expansion and electrification of the facilities. This will facilitate for future electrification of the sport,” says Bård Mikkelsen, Chairman of the board for Rudskogen Motorsports Center AS.
Lempäälä House is a modern building completed in 2020 in the municipal centre of Lempäälä. It will be supplied with a BESS with a rated capacity of 80 kWh and rated power of 40 kW.
”The pilot sounded immediately interesting and especially the application of demand response is very topical. We’re very excited to see the results so we can further apply them in our future projects as well,” says Ulla Palo-oja, Construction manager of Lempäälä municipality. The easy replicability of the demonstrations across Europe and beyond is one of the key objectives of the project.
The battery systems will operate and collect data for research until 2026. The operation of the systems will be optimized throughout this period based on the data and experience.
About TREASoURcE
TREASoURcE is an initiative funded by the European Union under the Horizon Europe research and innovation programme with a budget of EUR 9.99 million. The four-year project (2022-2026) is coordinated by VTT Technical Research Centre of Finland Ltd, and the consortium consists of 17 partners from six European countries. Project website: https://treasource.eu/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230322005363/en/
Contact information
More information:
Mathias Winther Thorsen, Battery Systems Engineer, ECO STOR AS
mathias.thorsen@eco-stor.no, +47 91395282
Fride Vullum-Bruer, Senior researcher, SINTEF Energy
fride.vullum.bruer@sintef.no, +47 98667654
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom